000007800312/312020Q3false00000780032020-01-012020-09-270000078003us-gaap:CommonStockMember2020-01-012020-09-270000078003pfe:NotesDue20220.250Member2020-01-012020-09-270000078003pfe:NotesDue20271.000Member2020-01-012020-09-27xbrli:shares00000780032020-11-02iso4217:USD00000780032020-06-292020-09-2700000780032019-07-012019-09-2900000780032019-01-012019-09-29iso4217:USDxbrli:shares00000780032020-09-2700000780032019-12-310000078003us-gaap:PreferredStockMember2020-06-280000078003us-gaap:CommonStockMember2020-06-280000078003us-gaap:AdditionalPaidInCapitalMember2020-06-280000078003us-gaap:TreasuryStockMember2020-06-280000078003us-gaap:RetainedEarningsMember2020-06-280000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-280000078003us-gaap:ParentMember2020-06-280000078003us-gaap:NoncontrollingInterestMember2020-06-2800000780032020-06-280000078003us-gaap:RetainedEarningsMember2020-06-292020-09-270000078003us-gaap:ParentMember2020-06-292020-09-270000078003us-gaap:NoncontrollingInterestMember2020-06-292020-09-270000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-292020-09-270000078003us-gaap:CommonStockMember2020-06-292020-09-270000078003us-gaap:AdditionalPaidInCapitalMember2020-06-292020-09-270000078003us-gaap:TreasuryStockMember2020-06-292020-09-270000078003us-gaap:PreferredStockMember2020-09-270000078003us-gaap:CommonStockMember2020-09-270000078003us-gaap:AdditionalPaidInCapitalMember2020-09-270000078003us-gaap:TreasuryStockMember2020-09-270000078003us-gaap:RetainedEarningsMember2020-09-270000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-270000078003us-gaap:ParentMember2020-09-270000078003us-gaap:NoncontrollingInterestMember2020-09-270000078003us-gaap:PreferredStockMember2019-06-300000078003us-gaap:CommonStockMember2019-06-300000078003us-gaap:AdditionalPaidInCapitalMember2019-06-300000078003us-gaap:TreasuryStockMember2019-06-300000078003us-gaap:RetainedEarningsMember2019-06-300000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300000078003us-gaap:ParentMember2019-06-300000078003us-gaap:NoncontrollingInterestMember2019-06-3000000780032019-06-300000078003us-gaap:RetainedEarningsMember2019-07-012019-09-290000078003us-gaap:ParentMember2019-07-012019-09-290000078003us-gaap:NoncontrollingInterestMember2019-07-012019-09-290000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-290000078003us-gaap:CommonStockMember2019-07-012019-09-290000078003us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-290000078003us-gaap:TreasuryStockMember2019-07-012019-09-290000078003us-gaap:PreferredStockMember2019-07-012019-09-290000078003us-gaap:PreferredStockMember2019-09-290000078003us-gaap:CommonStockMember2019-09-290000078003us-gaap:AdditionalPaidInCapitalMember2019-09-290000078003us-gaap:TreasuryStockMember2019-09-290000078003us-gaap:RetainedEarningsMember2019-09-290000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-290000078003us-gaap:ParentMember2019-09-290000078003us-gaap:NoncontrollingInterestMember2019-09-2900000780032019-09-290000078003us-gaap:PreferredStockMember2019-12-310000078003us-gaap:CommonStockMember2019-12-310000078003us-gaap:AdditionalPaidInCapitalMember2019-12-310000078003us-gaap:TreasuryStockMember2019-12-310000078003us-gaap:RetainedEarningsMember2019-12-310000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000078003us-gaap:ParentMember2019-12-310000078003us-gaap:NoncontrollingInterestMember2019-12-310000078003us-gaap:RetainedEarningsMember2020-01-012020-09-270000078003us-gaap:ParentMember2020-01-012020-09-270000078003us-gaap:NoncontrollingInterestMember2020-01-012020-09-270000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-270000078003us-gaap:CommonStockMember2020-01-012020-09-270000078003us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-270000078003us-gaap:TreasuryStockMember2020-01-012020-09-270000078003us-gaap:PreferredStockMember2020-01-012020-09-270000078003us-gaap:PreferredStockMember2018-12-310000078003us-gaap:CommonStockMember2018-12-310000078003us-gaap:AdditionalPaidInCapitalMember2018-12-310000078003us-gaap:TreasuryStockMember2018-12-310000078003us-gaap:RetainedEarningsMember2018-12-310000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000078003us-gaap:ParentMember2018-12-310000078003us-gaap:NoncontrollingInterestMember2018-12-3100000780032018-12-310000078003us-gaap:RetainedEarningsMember2019-01-012019-09-290000078003us-gaap:ParentMember2019-01-012019-09-290000078003us-gaap:NoncontrollingInterestMember2019-01-012019-09-290000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-290000078003us-gaap:CommonStockMember2019-01-012019-09-290000078003us-gaap:AdditionalPaidInCapitalMember2019-01-012019-09-290000078003us-gaap:TreasuryStockMember2019-01-012019-09-290000078003us-gaap:PreferredStockMember2019-01-012019-09-29xbrli:pure0000078003pfe:GSKConsumerHealthcareMember2019-09-290000078003pfe:GSKConsumerHealthcareMember2020-01-012020-09-270000078003pfe:GSKConsumerHealthcareMember2019-01-012019-09-29pfe:Operating_Segment00000780032019-01-012019-07-31pfe:Accounting_standard00000780032020-01-0100000780032019-01-010000078003us-gaap:AccountsReceivableMember2020-09-270000078003us-gaap:AccountsReceivableMember2019-12-310000078003us-gaap:OtherCurrentLiabilitiesMember2020-09-270000078003us-gaap:OtherCurrentLiabilitiesMember2019-12-310000078003us-gaap:OtherNoncurrentLiabilitiesMember2020-09-270000078003us-gaap:OtherNoncurrentLiabilitiesMember2019-12-310000078003pfe:ArrayMember2019-07-300000078003pfe:ArrayMember2019-07-302019-07-300000078003pfe:ArrayMemberus-gaap:DevelopedTechnologyRightsMember2019-07-300000078003pfe:ArrayMemberus-gaap:DevelopedTechnologyRightsMember2019-07-302019-07-300000078003pfe:ArrayMemberus-gaap:InProcessResearchAndDevelopmentMember2019-07-300000078003pfe:ArrayMemberus-gaap:LicensingAgreementsMember2019-07-300000078003pfe:LicensingAgreementsTechnologyInDevelopmentMemberpfe:ArrayMember2019-07-300000078003pfe:ArrayMemberpfe:LicensingAgreementsDevelopedTechnologyMember2019-07-300000078003pfe:ArrayMemberpfe:LicensingAgreementsDevelopedTechnologyMember2019-07-302019-07-300000078003pfe:ArrayMember2020-01-012020-09-270000078003pfe:GSKConsumerHealthcareMember2019-07-310000078003pfe:GSKConsumerHealthcareMemberpfe:GSKMember2019-07-310000078003pfe:GSKConsumerHealthcareMember2019-07-012019-09-290000078003pfe:GSKConsumerHealthcareMember2020-09-270000078003pfe:GSKConsumerHealthcareMember2019-12-310000078003pfe:GSKConsumerHealthcareMember2020-06-292020-09-270000078003pfe:GSKConsumerHealthcareMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-06-292020-09-270000078003pfe:GSKConsumerHealthcareMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-01-012020-09-270000078003pfe:GSKConsumerHealthcareMembersrt:MinimumMember2020-01-012020-09-270000078003pfe:GSKConsumerHealthcareMembersrt:MaximumMember2020-01-012020-09-270000078003us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberpfe:ConsumerHealthcareMember2019-07-012019-09-290000078003us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberpfe:ConsumerHealthcareMember2019-01-012019-09-290000078003pfe:GSKConsumerHealthcareMember2020-06-300000078003pfe:GSKConsumerHealthcareMember2020-04-012020-06-300000078003pfe:GSKConsumerHealthcareMember2019-10-012020-06-300000078003pfe:ValnevaSEMemberus-gaap:LicensingAgreementsMember2020-04-300000078003pfe:ValnevaSEMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:LicensingAgreementsMember2020-03-302020-06-280000078003pfe:ValnevaSEMemberus-gaap:LicensingAgreementsMember2020-01-012020-09-270000078003us-gaap:ResearchAndDevelopmentExpenseMemberpfe:BionTechMemberus-gaap:LicensingAgreementsMember2020-03-302020-06-280000078003pfe:BionTechMemberus-gaap:LicensingAgreementsMember2020-03-302020-06-280000078003pfe:BionTechMemberus-gaap:LicensingAgreementsMember2020-04-090000078003pfe:BionTechMemberus-gaap:LicensingAgreementsMember2020-04-092020-04-090000078003pfe:BionTechMemberus-gaap:LicensingAgreementsMember2020-07-012020-07-310000078003pfe:FocusedCompanyPlanMember2020-09-270000078003pfe:FocusedCompanyPlanMemberpfe:ManufacturingCostReductionMember2020-09-270000078003pfe:FocusedCompanyPlanMemberpfe:ManufacturingCostReductionMember2020-01-012020-09-270000078003pfe:FocusedCompanyPlanMember2019-10-012020-09-270000078003pfe:FocusedCompanyPlanMember2020-01-012020-09-270000078003pfe:TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember2019-01-012019-09-290000078003pfe:BusinessIntegrationCostsMemberpfe:ArrayMember2019-01-012019-09-290000078003pfe:BusinessIntegrationCostsMemberpfe:HospiraMember2019-01-012019-09-290000078003pfe:BusinessIntegrationCostsMember2019-01-012019-09-290000078003us-gaap:OtherNonoperatingIncomeExpenseMember2020-06-292020-09-270000078003us-gaap:OtherNonoperatingIncomeExpenseMember2019-07-012019-09-290000078003us-gaap:OtherNonoperatingIncomeExpenseMember2020-01-012020-09-270000078003us-gaap:OtherNonoperatingIncomeExpenseMember2019-01-012019-09-290000078003us-gaap:CostOfSalesMember2020-06-292020-09-270000078003us-gaap:CostOfSalesMember2019-07-012019-09-290000078003us-gaap:CostOfSalesMember2020-01-012020-09-270000078003us-gaap:CostOfSalesMember2019-01-012019-09-290000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-06-292020-09-270000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-07-012019-09-290000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-09-270000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-09-290000078003us-gaap:ResearchAndDevelopmentExpenseMember2020-06-292020-09-270000078003us-gaap:ResearchAndDevelopmentExpenseMember2019-07-012019-09-290000078003us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-270000078003us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMemberus-gaap:OperatingSegmentsMember2020-06-292020-09-270000078003pfe:UpjohnSegmentMemberus-gaap:OperatingSegmentsMember2020-06-292020-09-270000078003us-gaap:MaterialReconcilingItemsMember2020-06-292020-09-270000078003pfe:BiopharmaSegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-270000078003pfe:UpjohnSegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-270000078003us-gaap:MaterialReconcilingItemsMember2020-01-012020-09-270000078003pfe:BiopharmaSegmentMemberus-gaap:OperatingSegmentsMember2019-07-012019-09-290000078003pfe:UpjohnSegmentMemberus-gaap:OperatingSegmentsMember2019-07-012019-09-290000078003us-gaap:MaterialReconcilingItemsMember2019-07-012019-09-290000078003pfe:BiopharmaSegmentMemberus-gaap:OperatingSegmentsMember2019-01-012019-09-290000078003pfe:UpjohnSegmentMemberus-gaap:OperatingSegmentsMember2019-01-012019-09-290000078003us-gaap:MaterialReconcilingItemsMember2019-01-012019-09-290000078003pfe:ArrayMember2019-01-012019-09-290000078003pfe:ArrayMember2019-07-012019-09-290000078003us-gaap:EmployeeSeveranceMember2019-12-310000078003pfe:AssetImpairmentsMember2019-12-310000078003us-gaap:OtherRestructuringMember2019-12-310000078003us-gaap:EmployeeSeveranceMember2020-01-012020-09-270000078003pfe:AssetImpairmentsMember2020-01-012020-09-270000078003us-gaap:OtherRestructuringMember2020-01-012020-09-270000078003us-gaap:EmployeeSeveranceMember2020-09-270000078003pfe:AssetImpairmentsMember2020-09-270000078003us-gaap:OtherRestructuringMember2020-09-270000078003pfe:AllogeneMember2020-06-292020-09-270000078003pfe:AllogeneMember2020-01-012020-09-270000078003pfe:BioNTechSEMember2020-01-012020-09-270000078003pfe:CortexymeIncAndSpringWorksTherapeuticsIncMember2019-01-012019-09-290000078003pfe:CK1AssetsSoldToBiogenIncMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2020-09-270000078003pfe:PumaTechnologiesMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-270000078003us-gaap:CollaborativeArrangementMemberpfe:EliLillyCompanyMember2020-01-012020-09-270000078003pfe:MylanMemberus-gaap:CollaborativeArrangementMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMemberus-gaap:OperatingSegmentsMemberus-gaap:InProcessResearchAndDevelopmentMember2020-06-292020-09-270000078003pfe:BiopharmaSegmentMemberus-gaap:OperatingSegmentsMemberus-gaap:InProcessResearchAndDevelopmentMember2020-01-012020-09-270000078003pfe:GeneTherapiesMemberpfe:PfizersWorldwideResearchDevelopmentAndMedicalMemberus-gaap:InProcessResearchAndDevelopmentMember2019-01-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:KingMemberus-gaap:OperatingSegmentsMemberus-gaap:DevelopedTechnologyRightsMember2019-01-012019-09-290000078003pfe:AnacorMemberpfe:BiopharmaSegmentMemberus-gaap:OperatingSegmentsMemberus-gaap:DevelopedTechnologyRightsMember2019-01-012019-09-290000078003srt:SubsidiariesMemberpfe:UpjohnFinanceB.V.Member2020-06-292020-09-270000078003pfe:ViiVMember2020-06-292020-09-270000078003pfe:ViiVMember2020-01-012020-09-270000078003pfe:ViiVMember2020-01-012020-09-270000078003pfe:ViiVMember2019-07-012019-09-290000078003pfe:ViiVMember2019-01-012019-09-290000078003us-gaap:InProcessResearchAndDevelopmentMember2020-09-270000078003us-gaap:FairValueInputsLevel1Memberus-gaap:InProcessResearchAndDevelopmentMember2020-09-270000078003us-gaap:FairValueInputsLevel2Memberus-gaap:InProcessResearchAndDevelopmentMember2020-09-270000078003us-gaap:FairValueInputsLevel3Memberus-gaap:InProcessResearchAndDevelopmentMember2020-09-270000078003us-gaap:InProcessResearchAndDevelopmentMember2020-01-012020-09-270000078003us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2019-12-310000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2019-12-310000078003us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-09-270000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-09-270000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-09-270000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2020-01-012020-09-270000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2020-01-012020-09-270000078003us-gaap:AccumulatedTranslationAdjustmentMember2020-09-270000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-09-270000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-09-270000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2020-09-270000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2020-09-270000078003us-gaap:MoneyMarketFundsMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:MoneyMarketFundsMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:MoneyMarketFundsMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:MoneyMarketFundsMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-09-270000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-09-270000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:InterestRateContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:InterestRateContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:InterestRateContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:InterestRateContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:FairValueInputsLevel2Memberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-09-270000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-09-270000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310000078003us-gaap:CorporateDebtSecuritiesMemberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:CorporateDebtSecuritiesMemberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:CorporateDebtSecuritiesMemberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:CorporateDebtSecuritiesMemberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-270000078003us-gaap:FairValueInputsLevel2Memberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-270000078003us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherNoncurrentLiabilitiesMember2020-09-270000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2019-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherNoncurrentLiabilitiesMember2019-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2019-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-09-270000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherNoncurrentLiabilitiesMember2020-09-270000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-09-270000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2019-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherNoncurrentLiabilitiesMember2019-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2019-12-310000078003srt:SubsidiariesMemberpfe:UpjohnIncMember2020-01-012020-09-270000078003us-gaap:CarryingReportedAmountFairValueDisclosureMember2020-09-270000078003us-gaap:EstimateOfFairValueFairValueDisclosureMember2020-09-270000078003us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2020-09-270000078003us-gaap:CarryingReportedAmountFairValueDisclosureMember2019-12-310000078003us-gaap:EstimateOfFairValueFairValueDisclosureMember2019-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2019-12-310000078003us-gaap:ForeignGovernmentDebtSecuritiesMember2020-09-270000078003us-gaap:ForeignGovernmentDebtSecuritiesMember2019-12-310000078003us-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-09-270000078003us-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310000078003us-gaap:CorporateDebtSecuritiesMember2020-09-270000078003us-gaap:CorporateDebtSecuritiesMember2019-12-310000078003us-gaap:BankTimeDepositsMember2020-09-270000078003us-gaap:BankTimeDepositsMember2019-12-310000078003pfe:SeniorUnsecuredDebtZeroPointEightZeroZeroPercentDue2025Memberus-gaap:SeniorNotesMemberus-gaap:ParentMember2020-09-270000078003us-gaap:SeniorNotesMemberus-gaap:ParentMemberpfe:SeniorUnsecuredDebtOnePointSevenZeroZeroPercentDue2030Member2020-09-270000078003pfe:SeniorUnsecuredDebtTwoPointFiveFiveZeroPercentDue2040Memberus-gaap:SeniorNotesMemberus-gaap:ParentMember2020-09-270000078003us-gaap:SeniorNotesMemberus-gaap:ParentMemberpfe:SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2050Member2020-09-270000078003us-gaap:ParentMember2020-09-270000078003us-gaap:SeniorNotesMemberpfe:SeniorUnsecuredDebtOnePointOneTwoFivePercentDue2022Membersrt:SubsidiariesMemberpfe:UpjohnIncMember2020-09-270000078003us-gaap:SeniorNotesMemberpfe:SeniorUnsecuredDebtOnePointSixFiveZeroPercentDue2025Membersrt:SubsidiariesMemberpfe:UpjohnIncMember2020-09-270000078003pfe:SeniorUnsecuredDebtTwoPointThreeZeroZeroPercentDue2027Memberus-gaap:SeniorNotesMembersrt:SubsidiariesMemberpfe:UpjohnIncMember2020-09-270000078003us-gaap:SeniorNotesMemberpfe:SeniorUnsecuredDebtTwoPointSevenZeroZeroPercentDue2030Membersrt:SubsidiariesMemberpfe:UpjohnIncMember2020-09-270000078003us-gaap:SeniorNotesMembersrt:SubsidiariesMemberpfe:UpjohnIncMemberpfe:SeniorUnsecuredDebtThreePointEightFiveZeroPercentDue2040Member2020-09-270000078003pfe:SeniorUnsecuredDebtFourPointZeroZeroZeroPercentDue2050Memberus-gaap:SeniorNotesMembersrt:SubsidiariesMemberpfe:UpjohnIncMember2020-09-270000078003srt:SubsidiariesMemberpfe:UpjohnIncMember2020-09-270000078003us-gaap:SeniorNotesMembersrt:SubsidiariesMemberpfe:UpjohnFinanceB.V.Memberpfe:SeniorUnsecuredDebtZeroPointEightOneSixPercentDue2022Member2020-09-27iso4217:EUR0000078003us-gaap:SeniorNotesMembersrt:SubsidiariesMemberpfe:SeniorUnsecuredDebtOnePointZeroTwoThreePercentDue2024Memberpfe:UpjohnFinanceB.V.Member2020-09-270000078003us-gaap:SeniorNotesMemberpfe:SeniorUnsecuredDebtOnePointThreeSixTwoPercentDue2027Membersrt:SubsidiariesMemberpfe:UpjohnFinanceB.V.Member2020-09-270000078003pfe:SeniorUnsecuredDebtOnePointNineZeroEightPercentDue2032Memberus-gaap:SeniorNotesMembersrt:SubsidiariesMemberpfe:UpjohnFinanceB.V.Member2020-09-270000078003srt:SubsidiariesMemberpfe:UpjohnFinanceB.V.Member2020-09-270000078003us-gaap:SeniorNotesMembersrt:SubsidiariesMember2020-01-012020-09-270000078003us-gaap:SeniorNotesMember2020-09-270000078003us-gaap:SeniorNotesMemberpfe:SeniorUnsecuredDebtTwoPointSixTwoFivePercentDue2030Member2020-09-270000078003us-gaap:UnsecuredDebtMember2020-09-270000078003us-gaap:UnsecuredDebtMember2019-12-310000078003pfe:SeniorNotesDue2047Memberus-gaap:UnsecuredDebtMember2020-03-290000078003us-gaap:ForeignExchangeContractMember2020-01-012020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000078003us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-270000078003us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000078003us-gaap:DesignatedAsHedgingInstrumentMember2020-09-270000078003us-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2019-12-310000078003us-gaap:SalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-270000078003us-gaap:SalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-06-292020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-07-012019-09-290000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-06-292020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-07-012019-09-290000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2020-06-292020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2019-07-012019-09-290000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2020-06-292020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2019-07-012019-09-290000078003us-gaap:InterestRateContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-06-292020-09-270000078003us-gaap:InterestRateContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-07-012019-09-290000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2020-06-292020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2019-07-012019-09-290000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2020-06-292020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2019-07-012019-09-290000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyShortTermBorrowingsMember2020-06-292020-09-270000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyShortTermBorrowingsMember2019-07-012019-09-290000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyShortTermBorrowingsMember2020-06-292020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyShortTermBorrowingsMember2019-07-012019-09-290000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyLongTermDebtMember2020-06-292020-09-270000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyLongTermDebtMember2019-07-012019-09-290000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyLongTermDebtMember2020-06-292020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyLongTermDebtMember2019-07-012019-09-290000078003us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-06-292020-09-270000078003us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2019-07-012019-09-290000078003pfe:OtherIncomeDeductionsAndCostOfSalesMember2020-06-292020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMember2019-07-012019-09-290000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-01-012019-09-290000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-01-012019-09-290000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2020-01-012020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2019-01-012019-09-290000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2020-01-012020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2019-01-012019-09-290000078003us-gaap:InterestRateContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-270000078003us-gaap:InterestRateContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-01-012019-09-290000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2020-01-012020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2019-01-012019-09-290000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2020-01-012020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2019-01-012019-09-290000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyShortTermBorrowingsMember2020-01-012020-09-270000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyShortTermBorrowingsMember2019-01-012019-09-290000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyShortTermBorrowingsMember2020-01-012020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyShortTermBorrowingsMember2019-01-012019-09-290000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyLongTermDebtMember2020-01-012020-09-270000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyLongTermDebtMember2019-01-012019-09-290000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyLongTermDebtMember2020-01-012020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyLongTermDebtMember2019-01-012019-09-290000078003us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-01-012020-09-270000078003us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2019-01-012019-09-290000078003pfe:OtherIncomeDeductionsAndCostOfSalesMember2020-01-012020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMember2019-01-012019-09-290000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2020-06-292020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2020-01-012020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2019-07-012019-09-290000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2019-01-012019-09-290000078003pfe:ForeignCurrencyLongTermDebtMember2020-09-270000078003us-gaap:ShortTermInvestmentsMember2020-09-270000078003us-gaap:ShortTermInvestmentsMember2019-12-310000078003pfe:LongtermInvestmentsMember2020-09-270000078003pfe:LongtermInvestmentsMember2019-12-310000078003us-gaap:LongTermDebtMember2020-09-270000078003us-gaap:LongTermDebtMember2019-12-310000078003us-gaap:FinancialServicesSectorMember2020-01-012020-09-270000078003us-gaap:DevelopedTechnologyRightsMember2020-09-270000078003us-gaap:DevelopedTechnologyRightsMember2019-12-310000078003us-gaap:TradeNamesMember2020-09-270000078003us-gaap:TradeNamesMember2019-12-310000078003pfe:LicensingAgreementsAndOtherMember2020-09-270000078003pfe:LicensingAgreementsAndOtherMember2019-12-310000078003us-gaap:TradeNamesMember2020-09-270000078003us-gaap:TradeNamesMember2019-12-310000078003us-gaap:InProcessResearchAndDevelopmentMember2019-12-310000078003pfe:LicensingAgreementsAndOtherMember2020-09-270000078003pfe:LicensingAgreementsAndOtherMember2019-12-310000078003pfe:BraftoviMemberus-gaap:InProcessResearchAndDevelopmentMember2020-01-012020-09-270000078003pfe:BraftoviMemberus-gaap:DevelopedTechnologyRightsMember2020-01-012020-09-270000078003pfe:ArrayMemberus-gaap:DevelopedTechnologyRightsMember2020-01-012020-09-270000078003pfe:ArrayMemberus-gaap:LicensingAgreementsMember2020-01-012020-09-270000078003pfe:LicensingAgreementsAndOtherMemberpfe:ArrayMember2020-01-012020-09-270000078003pfe:BiopharmaSegmentMemberus-gaap:OperatingSegmentsMemberus-gaap:DevelopedTechnologyRightsMember2020-09-270000078003pfe:UpjohnSegmentMemberus-gaap:OperatingSegmentsMemberus-gaap:DevelopedTechnologyRightsMember2020-09-270000078003us-gaap:MaterialReconcilingItemsMemberpfe:PfizersWorldwideResearchDevelopmentAndMedicalMemberus-gaap:DevelopedTechnologyRightsMember2020-09-270000078003us-gaap:TradeNamesMemberpfe:BiopharmaSegmentMemberus-gaap:OperatingSegmentsMember2020-09-270000078003pfe:UpjohnSegmentMemberus-gaap:TradeNamesMemberus-gaap:OperatingSegmentsMember2020-09-270000078003us-gaap:TradeNamesMemberus-gaap:MaterialReconcilingItemsMemberpfe:PfizersWorldwideResearchDevelopmentAndMedicalMember2020-09-270000078003pfe:BiopharmaSegmentMemberus-gaap:OperatingSegmentsMemberus-gaap:TradeNamesMember2020-09-270000078003pfe:UpjohnSegmentMemberus-gaap:OperatingSegmentsMemberus-gaap:TradeNamesMember2020-09-270000078003us-gaap:MaterialReconcilingItemsMemberpfe:PfizersWorldwideResearchDevelopmentAndMedicalMemberus-gaap:TradeNamesMember2020-09-270000078003pfe:BiopharmaSegmentMemberus-gaap:OperatingSegmentsMemberus-gaap:InProcessResearchAndDevelopmentMember2020-09-270000078003pfe:UpjohnSegmentMemberus-gaap:OperatingSegmentsMemberus-gaap:InProcessResearchAndDevelopmentMember2020-09-270000078003us-gaap:MaterialReconcilingItemsMemberpfe:PfizersWorldwideResearchDevelopmentAndMedicalMemberus-gaap:InProcessResearchAndDevelopmentMember2020-09-270000078003pfe:LicensingAgreementsAndOtherMemberpfe:BiopharmaSegmentMemberus-gaap:OperatingSegmentsMember2020-09-270000078003pfe:UpjohnSegmentMemberpfe:LicensingAgreementsAndOtherMemberus-gaap:OperatingSegmentsMember2020-09-270000078003pfe:LicensingAgreementsAndOtherMemberus-gaap:MaterialReconcilingItemsMemberpfe:PfizersWorldwideResearchDevelopmentAndMedicalMember2020-09-270000078003pfe:LicensingAgreementsAndOtherMemberpfe:BiopharmaSegmentMemberus-gaap:OperatingSegmentsMember2020-09-270000078003pfe:UpjohnSegmentMemberpfe:LicensingAgreementsAndOtherMemberus-gaap:OperatingSegmentsMember2020-09-270000078003pfe:LicensingAgreementsAndOtherMemberus-gaap:MaterialReconcilingItemsMemberpfe:PfizersWorldwideResearchDevelopmentAndMedicalMember2020-09-270000078003us-gaap:FiniteLivedIntangibleAssetsMember2020-06-292020-09-270000078003us-gaap:FiniteLivedIntangibleAssetsMember2019-07-012019-09-290000078003us-gaap:FiniteLivedIntangibleAssetsMember2020-01-012020-09-270000078003us-gaap:FiniteLivedIntangibleAssetsMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMemberus-gaap:OperatingSegmentsMember2019-12-310000078003pfe:UpjohnSegmentMemberus-gaap:OperatingSegmentsMember2019-12-310000078003pfe:BiopharmaSegmentMemberus-gaap:OperatingSegmentsMember2020-09-270000078003pfe:UpjohnSegmentMemberus-gaap:OperatingSegmentsMember2020-09-270000078003country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2020-06-292020-09-270000078003country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2019-07-012019-09-290000078003us-gaap:NonqualifiedPlanMembercountry:USus-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember2020-06-292020-09-270000078003us-gaap:NonqualifiedPlanMembercountry:USus-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember2019-07-012019-09-290000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-06-292020-09-270000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-07-012019-09-290000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-06-292020-09-270000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-07-012019-09-290000078003country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2020-01-012020-09-270000078003country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2019-01-012019-09-290000078003us-gaap:NonqualifiedPlanMembercountry:USus-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember2020-01-012020-09-270000078003us-gaap:NonqualifiedPlanMembercountry:USus-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember2019-01-012019-09-290000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-01-012020-09-270000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-01-012019-09-290000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-09-270000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-01-012019-09-290000078003country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2020-09-270000078003us-gaap:NonqualifiedPlanMembercountry:USus-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember2020-09-270000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-09-270000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-09-270000078003country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2020-09-012020-09-270000078003us-gaap:CommonStockMember2020-05-042020-05-0400000780032020-05-0400000780032019-12-132019-12-1300000780032018-12-142018-12-1400000780032020-04-232020-04-2300000780032019-04-252019-04-2500000780032020-06-252020-06-2500000780032019-06-272019-06-2700000780032020-09-242020-09-2400000780032019-09-242019-09-24pfe:Patents0000078003pfe:PatentInfringementMember2017-10-012017-10-310000078003us-gaap:JudicialRulingMemberpfe:PatentInfringementMember2018-06-012018-06-300000078003us-gaap:PendingLitigationMemberpfe:XeljanzMemberpfe:PatentInfringementMemberpfe:PfizerVersusZydusMember2017-03-012017-03-310000078003pfe:PfizerVersusGenericCompaniesMemberus-gaap:PendingLitigationMemberpfe:PatentInfringementMember2019-03-012019-03-310000078003us-gaap:SettledLitigationMemberpfe:PfizerVersusViwitPharmaceuticalCo.Ltd.Memberpfe:PatentInfringementMember2020-01-012020-01-31pfe:plaintiff0000078003pfe:NHSScotlandvs.DrReddysMemberpfe:PatentInfringementMemberus-gaap:PendingLitigationMember2020-07-012020-07-31pfe:Defendant0000078003pfe:EliquisMemberpfe:PfizerandBMSVersusSeveralGenericManufacturersMemberus-gaap:PendingLitigationMemberpfe:PatentInfringementMember2017-02-012017-04-30pfe:lawsuit0000078003pfe:EpiPenMembersrt:MinimumMember2020-09-27pfe:manufacturer0000078003pfe:DocetaxelMemberus-gaap:PendingLitigationMemberpfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember2018-10-012018-10-31pfe:class_action00000780032017-11-012017-11-30pfe:lagoon0000078003pfe:EnvironmentalRemediationLitigationMember2013-03-012013-03-310000078003pfe:EnvironmentalRemediationLitigationMember2018-09-012018-09-300000078003pfe:ClassActionVersusWyethMemberus-gaap:SettledLitigationMemberpfe:HormoneTherapyProductsMember2020-03-302020-06-280000078003us-gaap:OperatingSegmentsMember2020-06-292020-09-270000078003us-gaap:OperatingSegmentsMember2019-07-012019-09-290000078003us-gaap:CorporateNonSegmentMember2020-06-292020-09-270000078003us-gaap:CorporateNonSegmentMember2019-07-012019-09-290000078003pfe:PurchaseAccountingAdjustmentsMemberus-gaap:MaterialReconcilingItemsMember2020-06-292020-09-270000078003pfe:PurchaseAccountingAdjustmentsMemberus-gaap:MaterialReconcilingItemsMember2019-07-012019-09-290000078003us-gaap:MaterialReconcilingItemsMemberpfe:BusinessCombinationsAcquisitionRelatedCostsMember2020-06-292020-09-270000078003us-gaap:MaterialReconcilingItemsMemberpfe:BusinessCombinationsAcquisitionRelatedCostsMember2019-07-012019-09-290000078003us-gaap:MaterialReconcilingItemsMemberpfe:CertainSignificantItemsMember2020-06-292020-09-270000078003us-gaap:MaterialReconcilingItemsMemberpfe:CertainSignificantItemsMember2019-07-012019-09-290000078003us-gaap:OperatingSegmentsMember2020-01-012020-09-270000078003us-gaap:OperatingSegmentsMember2019-01-012019-09-290000078003us-gaap:CorporateNonSegmentMember2020-01-012020-09-270000078003us-gaap:CorporateNonSegmentMember2019-01-012019-09-290000078003pfe:PurchaseAccountingAdjustmentsMemberus-gaap:MaterialReconcilingItemsMember2020-01-012020-09-270000078003pfe:PurchaseAccountingAdjustmentsMemberus-gaap:MaterialReconcilingItemsMember2019-01-012019-09-290000078003us-gaap:MaterialReconcilingItemsMemberpfe:BusinessCombinationsAcquisitionRelatedCostsMember2020-01-012020-09-270000078003us-gaap:MaterialReconcilingItemsMemberpfe:BusinessCombinationsAcquisitionRelatedCostsMember2019-01-012019-09-290000078003us-gaap:MaterialReconcilingItemsMemberpfe:CertainSignificantItemsMember2020-01-012020-09-270000078003us-gaap:MaterialReconcilingItemsMemberpfe:CertainSignificantItemsMember2019-01-012019-09-290000078003country:US2020-06-292020-09-270000078003country:US2019-07-012019-09-290000078003country:US2020-01-012020-09-270000078003country:US2019-01-012019-09-290000078003pfe:DevelopedEuropeMember2020-06-292020-09-270000078003pfe:DevelopedEuropeMember2019-07-012019-09-290000078003pfe:DevelopedEuropeMember2020-01-012020-09-270000078003pfe:DevelopedEuropeMember2019-01-012019-09-290000078003pfe:DevelopedRestOfWorldMember2020-06-292020-09-270000078003pfe:DevelopedRestOfWorldMember2019-07-012019-09-290000078003pfe:DevelopedRestOfWorldMember2020-01-012020-09-270000078003pfe:DevelopedRestOfWorldMember2019-01-012019-09-290000078003pfe:EmergingMarketsMember2020-06-292020-09-270000078003pfe:EmergingMarketsMember2019-07-012019-09-290000078003pfe:EmergingMarketsMember2020-01-012020-09-270000078003pfe:EmergingMarketsMember2019-01-012019-09-290000078003currency:EURpfe:DevelopedEuropeMember2020-06-292020-09-270000078003currency:EURpfe:DevelopedEuropeMember2019-07-012019-09-290000078003currency:EURpfe:DevelopedEuropeMember2020-01-012020-09-270000078003currency:EURpfe:DevelopedEuropeMember2019-01-012019-09-290000078003pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2020-06-292020-09-270000078003pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2019-07-012019-09-290000078003pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2020-01-012020-09-270000078003pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2020-06-292020-09-270000078003pfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2019-07-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2020-01-012020-09-270000078003pfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2019-01-012019-09-290000078003pfe:EliquisMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2020-06-292020-09-270000078003pfe:EliquisMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2019-07-012019-09-290000078003pfe:EliquisMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2020-01-012020-09-270000078003pfe:EliquisMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2019-01-012019-09-290000078003pfe:ChantixChampixMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2020-06-292020-09-270000078003pfe:ChantixChampixMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2019-07-012019-09-290000078003pfe:ChantixChampixMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2020-01-012020-09-270000078003pfe:ChantixChampixMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2019-01-012019-09-290000078003pfe:PremarinFamilyMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2020-06-292020-09-270000078003pfe:PremarinFamilyMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2019-07-012019-09-290000078003pfe:PremarinFamilyMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2020-01-012020-09-270000078003pfe:PremarinFamilyMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:BMP2Memberpfe:InternalMedicineMember2020-06-292020-09-270000078003pfe:BiopharmaSegmentMemberpfe:BMP2Memberpfe:InternalMedicineMember2019-07-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:BMP2Memberpfe:InternalMedicineMember2020-01-012020-09-270000078003pfe:BiopharmaSegmentMemberpfe:BMP2Memberpfe:InternalMedicineMember2019-01-012019-09-290000078003pfe:ToviazMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2020-06-292020-09-270000078003pfe:ToviazMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2019-07-012019-09-290000078003pfe:ToviazMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2020-01-012020-09-270000078003pfe:ToviazMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2019-01-012019-09-290000078003pfe:AllOtherInternalMedicineMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2020-06-292020-09-270000078003pfe:AllOtherInternalMedicineMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2019-07-012019-09-290000078003pfe:AllOtherInternalMedicineMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2020-01-012020-09-270000078003pfe:AllOtherInternalMedicineMemberpfe:BiopharmaSegmentMemberpfe:InternalMedicineMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:BiopharmaSegmentMemberpfe:OncologyMember2019-07-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:BiopharmaSegmentMemberpfe:OncologyMember2019-01-012019-09-290000078003pfe:IbranceMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:IbranceMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2019-07-012019-09-290000078003pfe:IbranceMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:IbranceMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:OncologyMemberpfe:XtandiAllianceRevenuesMember2020-06-292020-09-270000078003pfe:BiopharmaSegmentMemberpfe:OncologyMemberpfe:XtandiAllianceRevenuesMember2019-07-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:OncologyMemberpfe:XtandiAllianceRevenuesMember2020-01-012020-09-270000078003pfe:BiopharmaSegmentMemberpfe:OncologyMemberpfe:XtandiAllianceRevenuesMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:OncologyMemberpfe:SutentMember2020-06-292020-09-270000078003pfe:BiopharmaSegmentMemberpfe:OncologyMemberpfe:SutentMember2019-07-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:OncologyMemberpfe:SutentMember2020-01-012020-09-270000078003pfe:BiopharmaSegmentMemberpfe:OncologyMemberpfe:SutentMember2019-01-012019-09-290000078003pfe:InlytaMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:InlytaMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2019-07-012019-09-290000078003pfe:InlytaMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:InlytaMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:XalkoriMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:BiopharmaSegmentMemberpfe:XalkoriMemberpfe:OncologyMember2019-07-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:XalkoriMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:BiopharmaSegmentMemberpfe:XalkoriMemberpfe:OncologyMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:OncologyMemberpfe:BosulifMember2020-06-292020-09-270000078003pfe:BiopharmaSegmentMemberpfe:OncologyMemberpfe:BosulifMember2019-07-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:OncologyMemberpfe:BosulifMember2020-01-012020-09-270000078003pfe:BiopharmaSegmentMemberpfe:OncologyMemberpfe:BosulifMember2019-01-012019-09-290000078003pfe:RetacritMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:RetacritMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2019-07-012019-09-290000078003pfe:RetacritMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:RetacritMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2019-01-012019-09-290000078003pfe:LorbrenaMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:LorbrenaMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2019-07-012019-09-290000078003pfe:LorbrenaMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:LorbrenaMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:BraftoviMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:BiopharmaSegmentMemberpfe:BraftoviMemberpfe:OncologyMember2019-07-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:BraftoviMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:BiopharmaSegmentMemberpfe:BraftoviMemberpfe:OncologyMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:MektoviMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:BiopharmaSegmentMemberpfe:MektoviMemberpfe:OncologyMember2019-07-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:MektoviMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:BiopharmaSegmentMemberpfe:MektoviMemberpfe:OncologyMember2019-01-012019-09-290000078003pfe:RuxienceMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:RuxienceMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2019-07-012019-09-290000078003pfe:RuxienceMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:RuxienceMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2019-01-012019-09-290000078003pfe:OtherOncologyProductsMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:OtherOncologyProductsMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2019-07-012019-09-290000078003pfe:OtherOncologyProductsMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:OtherOncologyProductsMemberpfe:BiopharmaSegmentMemberpfe:OncologyMember2019-01-012019-09-290000078003pfe:HospitalMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:HospitalMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:HospitalMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:HospitalMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:HospitalMemberpfe:SulperazonMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:HospitalMemberpfe:SulperazonMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:HospitalMemberpfe:SulperazonMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:HospitalMemberpfe:SulperazonMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:HospitalMemberpfe:MedrolMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:HospitalMemberpfe:MedrolMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:HospitalMemberpfe:MedrolMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:HospitalMemberpfe:MedrolMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:HospitalMemberpfe:BiopharmaSegmentMemberpfe:ZithromaxZmaxMember2020-06-292020-09-270000078003pfe:HospitalMemberpfe:BiopharmaSegmentMemberpfe:ZithromaxZmaxMember2019-07-012019-09-290000078003pfe:HospitalMemberpfe:BiopharmaSegmentMemberpfe:ZithromaxZmaxMember2020-01-012020-09-270000078003pfe:HospitalMemberpfe:BiopharmaSegmentMemberpfe:ZithromaxZmaxMember2019-01-012019-09-290000078003pfe:HospitalMemberpfe:BiopharmaSegmentMemberpfe:PrecedexMember2020-06-292020-09-270000078003pfe:HospitalMemberpfe:BiopharmaSegmentMemberpfe:PrecedexMember2019-07-012019-09-290000078003pfe:HospitalMemberpfe:BiopharmaSegmentMemberpfe:PrecedexMember2020-01-012020-09-270000078003pfe:HospitalMemberpfe:BiopharmaSegmentMemberpfe:PrecedexMember2019-01-012019-09-290000078003pfe:HospitalMemberpfe:BiopharmaSegmentMemberpfe:VfendMember2020-06-292020-09-270000078003pfe:HospitalMemberpfe:BiopharmaSegmentMemberpfe:VfendMember2019-07-012019-09-290000078003pfe:HospitalMemberpfe:BiopharmaSegmentMemberpfe:VfendMember2020-01-012020-09-270000078003pfe:HospitalMemberpfe:BiopharmaSegmentMemberpfe:VfendMember2019-01-012019-09-290000078003pfe:PanzygaMemberpfe:HospitalMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:PanzygaMemberpfe:HospitalMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:PanzygaMemberpfe:HospitalMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:PanzygaMemberpfe:HospitalMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:HospitalMemberpfe:FragminMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:HospitalMemberpfe:FragminMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:HospitalMemberpfe:FragminMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:HospitalMemberpfe:FragminMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:HospitalMemberpfe:ZyvoxMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:HospitalMemberpfe:ZyvoxMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:HospitalMemberpfe:ZyvoxMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:HospitalMemberpfe:ZyvoxMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:HospitalMemberpfe:PfizerCentreOneMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:HospitalMemberpfe:PfizerCentreOneMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:HospitalMemberpfe:PfizerCentreOneMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:HospitalMemberpfe:PfizerCentreOneMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:HospitalMemberpfe:OtherAntiinfectivesMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:HospitalMemberpfe:OtherAntiinfectivesMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:HospitalMemberpfe:OtherAntiinfectivesMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:HospitalMemberpfe:OtherAntiinfectivesMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:HospitalMemberpfe:OtherHospitalProductsMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:HospitalMemberpfe:OtherHospitalProductsMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:HospitalMemberpfe:OtherHospitalProductsMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:HospitalMemberpfe:OtherHospitalProductsMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:VaccinesMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:VaccinesMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:VaccinesMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:VaccinesMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:VaccinesMemberpfe:PrevnarPrevenarFamilyMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:VaccinesMemberpfe:PrevnarPrevenarFamilyMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:VaccinesMemberpfe:PrevnarPrevenarFamilyMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:VaccinesMemberpfe:PrevnarPrevenarFamilyMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:VaccinesMemberpfe:NimenrixMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:VaccinesMemberpfe:NimenrixMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:VaccinesMemberpfe:NimenrixMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:VaccinesMemberpfe:NimenrixMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:VaccinesMemberpfe:BiopharmaSegmentMemberpfe:FSMEIMMUNTicoVacMember2020-06-292020-09-270000078003pfe:VaccinesMemberpfe:BiopharmaSegmentMemberpfe:FSMEIMMUNTicoVacMember2019-07-012019-09-290000078003pfe:VaccinesMemberpfe:BiopharmaSegmentMemberpfe:FSMEIMMUNTicoVacMember2020-01-012020-09-270000078003pfe:VaccinesMemberpfe:BiopharmaSegmentMemberpfe:FSMEIMMUNTicoVacMember2019-01-012019-09-290000078003pfe:VaccinesMemberpfe:OtherVaccinesProductsMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:VaccinesMemberpfe:OtherVaccinesProductsMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:VaccinesMemberpfe:OtherVaccinesProductsMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:VaccinesMemberpfe:OtherVaccinesProductsMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMember2020-06-292020-09-270000078003pfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMember2019-07-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMember2020-01-012020-09-270000078003pfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:XeljanzMemberpfe:InflammationandImmunologyMember2020-06-292020-09-270000078003pfe:BiopharmaSegmentMemberpfe:XeljanzMemberpfe:InflammationandImmunologyMember2019-07-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:XeljanzMemberpfe:InflammationandImmunologyMember2020-01-012020-09-270000078003pfe:BiopharmaSegmentMemberpfe:XeljanzMemberpfe:InflammationandImmunologyMember2019-01-012019-09-290000078003pfe:EnbrelMemberpfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMember2020-06-292020-09-270000078003pfe:EnbrelMemberpfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMember2019-07-012019-09-290000078003pfe:EnbrelMemberpfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMember2020-01-012020-09-270000078003pfe:EnbrelMemberpfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMember2019-01-012019-09-290000078003pfe:InflectraRemsimaMemberpfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMember2020-06-292020-09-270000078003pfe:InflectraRemsimaMemberpfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMember2019-07-012019-09-290000078003pfe:InflectraRemsimaMemberpfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMember2020-01-012020-09-270000078003pfe:InflectraRemsimaMemberpfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMember2019-01-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMemberpfe:AllOtherInflammationandImmunologyProductsMember2020-06-292020-09-270000078003pfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMemberpfe:AllOtherInflammationandImmunologyProductsMember2019-07-012019-09-290000078003pfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMemberpfe:AllOtherInflammationandImmunologyProductsMember2020-01-012020-09-270000078003pfe:BiopharmaSegmentMemberpfe:InflammationandImmunologyMemberpfe:AllOtherInflammationandImmunologyProductsMember2019-01-012019-09-290000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:RareDiseaseMemberpfe:VyndaqelMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:RareDiseaseMemberpfe:VyndaqelMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:RareDiseaseMemberpfe:VyndaqelMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:RareDiseaseMemberpfe:VyndaqelMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:BeneFIXMemberpfe:RareDiseaseMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:BeneFIXMemberpfe:RareDiseaseMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:BeneFIXMemberpfe:RareDiseaseMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:BeneFIXMemberpfe:RareDiseaseMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:RareDiseaseMemberpfe:GenotropinMemberpfe:BiopharmaSegmentMember2020-06-292020-09-270000078003pfe:RareDiseaseMemberpfe:GenotropinMemberpfe:BiopharmaSegmentMember2019-07-012019-09-290000078003pfe:RareDiseaseMemberpfe:GenotropinMemberpfe:BiopharmaSegmentMember2020-01-012020-09-270000078003pfe:RareDiseaseMemberpfe:GenotropinMemberpfe:BiopharmaSegmentMember2019-01-012019-09-290000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMemberpfe:ReFactoAfXynthaMember2020-06-292020-09-270000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMemberpfe:ReFactoAfXynthaMember2019-07-012019-09-290000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMemberpfe:ReFactoAfXynthaMember2020-01-012020-09-270000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMemberpfe:ReFactoAfXynthaMember2019-01-012019-09-290000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMemberpfe:SomavertMember2020-06-292020-09-270000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMemberpfe:SomavertMember2019-07-012019-09-290000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMemberpfe:SomavertMember2020-01-012020-09-270000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMemberpfe:SomavertMember2019-01-012019-09-290000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMemberpfe:AllOtherRareDiseaseProductsMember2020-06-292020-09-270000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMemberpfe:AllOtherRareDiseaseProductsMember2019-07-012019-09-290000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMemberpfe:AllOtherRareDiseaseProductsMember2020-01-012020-09-270000078003pfe:RareDiseaseMemberpfe:BiopharmaSegmentMemberpfe:AllOtherRareDiseaseProductsMember2019-01-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMember2020-06-292020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMember2019-07-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMember2020-01-012020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMember2019-01-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:LipitorMember2020-06-292020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:LipitorMember2019-07-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:LipitorMember2020-01-012020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:LipitorMember2019-01-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:LyricaMember2020-06-292020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:LyricaMember2019-07-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:LyricaMember2020-01-012020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:LyricaMember2019-01-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:NorvascMember2020-06-292020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:NorvascMember2019-07-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:NorvascMember2020-01-012020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:NorvascMember2019-01-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:CelebrexMember2020-06-292020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:CelebrexMember2019-07-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:CelebrexMember2020-01-012020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:CelebrexMember2019-01-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:ViagraMember2020-06-292020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:ViagraMember2019-07-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:ViagraMember2020-01-012020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:ViagraMember2019-01-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:EffexorMember2020-06-292020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:EffexorMember2019-07-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:EffexorMember2020-01-012020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:EffexorMember2019-01-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:ZoloftMember2020-06-292020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:ZoloftMember2019-07-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:ZoloftMember2020-01-012020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:ZoloftMember2019-01-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:EpiPenMember2020-06-292020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:EpiPenMember2019-07-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:EpiPenMember2020-01-012020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:EpiPenMember2019-01-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:XalatanXalacomMember2020-06-292020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:XalatanXalacomMember2019-07-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:XalatanXalacomMember2020-01-012020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:XalatanXalacomMember2019-01-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:XanaxMember2020-06-292020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:XanaxMember2019-07-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:XanaxMember2020-01-012020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:XanaxMember2019-01-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:AllOtherUpjohnProductsMember2020-06-292020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:AllOtherUpjohnProductsMember2019-07-012019-09-290000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:AllOtherUpjohnProductsMember2020-01-012020-09-270000078003pfe:UpjohnSegmentMemberpfe:UpjohnReportingUnitMemberpfe:AllOtherUpjohnProductsMember2019-01-012019-09-290000078003pfe:ConsumerHealthcareMemberpfe:ConsumerHealthcareReportingUnitMember2020-06-292020-09-270000078003pfe:ConsumerHealthcareMemberpfe:ConsumerHealthcareReportingUnitMember2019-07-012019-09-290000078003pfe:ConsumerHealthcareMemberpfe:ConsumerHealthcareReportingUnitMember2020-01-012020-09-270000078003pfe:ConsumerHealthcareMemberpfe:ConsumerHealthcareReportingUnitMember2019-01-012019-09-290000078003pfe:TotalAllianceBiopharmaceuticalsMemberpfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2020-06-292020-09-270000078003pfe:TotalAllianceBiopharmaceuticalsMemberpfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2019-07-012019-09-290000078003pfe:TotalAllianceBiopharmaceuticalsMemberpfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2020-01-012020-09-270000078003pfe:TotalAllianceBiopharmaceuticalsMemberpfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2019-01-012019-09-290000078003pfe:TotalBiosimilarsMemberpfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2020-06-292020-09-270000078003pfe:TotalBiosimilarsMemberpfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2019-07-012019-09-290000078003pfe:TotalBiosimilarsMemberpfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2020-01-012020-09-270000078003pfe:TotalBiosimilarsMemberpfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2019-01-012019-09-290000078003pfe:TotalSterileInjectablePharmaceuticalsMemberpfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2020-06-292020-09-270000078003pfe:TotalSterileInjectablePharmaceuticalsMemberpfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2019-07-012019-09-290000078003pfe:TotalSterileInjectablePharmaceuticalsMemberpfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2020-01-012020-09-270000078003pfe:TotalSterileInjectablePharmaceuticalsMemberpfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember2019-01-012019-09-290000078003pfe:ViatrisMemberus-gaap:SubsequentEventMembersrt:ScenarioForecastMember2020-11-160000078003pfe:ViatrisMemberus-gaap:SubsequentEventMembersrt:ScenarioForecastMemberpfe:MylanMember2020-11-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 27, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______


COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware13-5315170
(State of Incorporation)(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York  10017
(Address of principal executive offices)  (zip code)
(212) 733-2323
(Registrant’s telephone number)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.05 par valuePFENew York Stock Exchange
0.250% Notes due 2022PFE22New York Stock Exchange
1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YesxNo

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
YesxNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x              Accelerated filer                 Non-accelerated filer            Smaller reporting company      Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YesNo
x

At November 2, 2020, 5,558,396,599 shares of the issuer’s voting common stock were outstanding.



Table of Contents
Page
 
 
Condensed Consolidated Statements of Income for the three and nine months ended September 27, 2020 and
September 29, 2019
Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 27, 2020 and September 29, 2019
Condensed Consolidated Balance Sheets as of September 27, 2020 and December 31, 2019
Condensed Consolidated Statements of Equity for the three and nine months ended September 27, 2020 and
September 29, 2019
Condensed Consolidated Statements of Cash Flows for the nine months ended September 27, 2020 and
September 29, 2019
Item 2.
 
Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
 
 
 
 
 
 
 
 
 
2


GLOSSARY OF DEFINED TERMS

Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined:
2019 Financial ReportFinancial Report for the fiscal year ended December 31, 2019, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2019
2019 Form 10-KAnnual Report on Form 10-K for the fiscal year ended December 31, 2019
ACA (Also referred to as U.S. Healthcare Legislation)U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
ACIPAdvisory Committee on Immunization Practices
ALKanaplastic lymphoma kinase
Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
AllogeneAllogene Therapeutics, Inc.
AMLAcute Myeloid Leukemia
AnacorAnacor Pharmaceuticals, Inc.
ArrayArray BioPharma Inc.
AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ATTR-CMtransthyretin amyloid cardiomyopathy
BambooBamboo Therapeutics, Inc.
BioNTechBioNTech SE
BiopharmaPfizer Biopharmaceuticals Group
BMSBristol-Myers Squibb Company
CDCU.S. Centers for Disease Control and Prevention
cGMPcurrent Good Manufacturing Practices
CHMPCommittee for Medicinal Products for Human Use
COVID-19novel coronavirus disease of 2019
Developed Europe
Includes the following markets: Western Europe, Scandinavian countries and Finland
Developed MarketsU.S., Developed Europe, Japan, Canada, South Korea, Australia and New Zealand
Developed Rest of World
Includes the following markets: Japan, Canada, South Korea, Australia and New Zealand
EMAEuropean Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey
EPSearnings per share
EUEuropean Union
Exchange ActSecurities Exchange Act of 1934, as amended
FASBFinancial Accounting Standards Board
FDAU.S. Food and Drug Administration
FTCU.S. Federal Trade Commission
GAAPGenerally Accepted Accounting Principles
GISTgastrointestinal stromal tumors
GPDGlobal Product Development organization
GSKGlaxoSmithKline plc
hGH-CTPhuman growth hormone
HospiraHospira, Inc.
IBTIncome before tax
IPR&Din-process research and development
IRSU.S. Internal Revenue Service
IVintravenous
J&JJohnson & Johnson
JVJoint Venture
KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
LDLlow density lipoprotein
LIBORLondon Interbank Offered Rate
LillyEli Lilly & Company
MCOmanaged care organization
3


GLOSSARY OF DEFINED TERMS
- continued -
mCRCmetastatic colorectal cancer
mCRPC
metastatic castration-resistant prostate cancer
mCSPC
metastatic castration-sensitive prostate cancer
mRNAmessenger ribonucleic acid
MD&AManagement’s Discussion and Analysis of Financial Condition and Results of Operations
MedivationMedivation LLC (formerly Medivation, Inc.)
MeridianMeridian Medical Technologies, Inc.
Moody’sMoody’s Investors Service
MylanMylan N.V.
NDAnew drug application
nmCRPC
non-metastatic castration-resistant prostate cancer
NSCLCnon-small cell lung cancer
OPKOOPKO Health, Inc.
PARPpoly ADP ribose polymerase
PBMpharmacy benefit manager
PharmaciaPharmacia Corporation
PP&Eproperty, plant & equipment
PsApsoriatic arthritis
Quarterly Report on Form 10-QQuarterly Report on Form 10-Q for the quarterly period ended September 27, 2020
RArheumatoid arthritis
RCCrenal cell carcinoma
R&Dresearch and development
RNAribonucleic acid
SandozSandoz, Inc., a division of Novartis AG
SECU.S. Securities and Exchange Commission
SI&Aselling, informational and administrative
S&PStandard and Poor’s
TCJAlegislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017
TherachonTherachon Holding AG
UCulcerative colitis
U.K.United Kingdom
U.S.United States
ValnevaValneva SE
ViiVViiV Healthcare Limited
VBPVolume-based procurement
WRDMWorldwide Research, Development and Medical

4


PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
 Three Months EndedNine Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)September 27,
2020
September 29,
2019
September 27,
2020
September 29,
2019
Revenues$12,131 $12,680 $35,961 $39,062 
Costs and expenses:
Cost of sales(a)
2,529 2,602 7,188 7,611 
Selling, informational and administrative expenses(a)
3,016 3,260 8,919 10,110 
Research and development expenses(a)
2,360 2,283 6,216 5,827 
Amortization of intangible assets898 1,212 2,688 3,578 
Restructuring charges and certain acquisition-related costs
4 365 435 295 
(Gain) on completion of Consumer Healthcare JV transaction
 (8,087)(6)(8,087)
Other (income)/deductions––net
1,148 319 507 537 
Income from continuing operations before provision/(benefit) for taxes on income2,176 10,727 10,014 19,190 
Provision/(benefit) for taxes on income(26)3,047 968 2,566 
Income from continuing operations2,202 7,680 9,046 16,625 
Discontinued operations––net of tax 4  4